Safety of allogeneic hematopoietic stem cell transplantation in beta-thalassemia patients with chronic hepatitis C infections treated at a pediatric center.
allogeneic stem cell transplant
beta-thalassemia
hepatitis C
reduced-intensity conditioning
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
05
03
2019
revised:
30
04
2019
accepted:
23
05
2019
pubmed:
19
6
2019
medline:
14
7
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
The outcome of allogeneic HCT in patients previously infected with HCV is a widely debated topic and rarely reported in the pediatric and young adult age group given the small population of affected patients. New medications directly targeting HCV have induced virologic cures for over 90% of patients, and their use in the pretransplant setting may improve outcomes for patients infected with HCV. We describe two patients with transfusion-dependent beta-thalassemia major who underwent matched sibling donor bone marrow transplantation, one with a myeloablative regimen and one with a reduced-intensity conditioning regimen. Allogeneic HCT appears feasible in patients with HCV infection that clear viremia prior to conditioning therapy and with a reduced-intensity conditioning regimen. Further investigation is warranted to better define transplant risks in this population.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13520Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811-820.
Peffault de Latour R, Asselah T, Lévy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2005;36(8):709-713.
Varma A, Saliba RM, Torres HA, et al. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant. 2016;51(7):999-1001.
Mallet V, van Bömmel F, Doerig C et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16(5):606-617.
Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant. 2016;22(4):717-722.
Torres HA, Chong PP, De Lima M, et al. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biol Blood Marrow Transplant. 2015;21(11):1870-1882.
Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, Pourfathollah AA, Haghbin A. Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran. Int J Prev Med. 2015;6:89.
Chern JPS, Syi SU, Lin K-H, et al. Survival, mortality, and complications in patients with beta-thalassemia major in Northern Taiwan. Pediatr Blood Cancer. 2007;48(5):550-554.
Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011;117(5):1745-1750.
Strasser SI, Myerson D, Spurgeon CL et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology. 1999;29(6):1893-1899.
Ivantes CAP, Amarante H, Ioshii SO, Pasquini R. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant. 2004;33(12):1181-1185.
Ljungman P, Locasciulli A, de Soria VG, et al. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant. 2012;47(9):1217-1221.
de Latour P, Régis VL, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103(5):1618-1624.
Castellino S, Lensing S, Riely C, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children’s Research Hospital Hepatitis C Seropositive Cohort. Blood. 2004;103(7):2460-2466.
Sood V, Chawla J, Lal BB, Khanna R, Bihari C, Alam S. Hepatic dysfunction in a child post bone marrow transplantation. J Clin Exp Hepatol. 2018;8(3):327-331.
Thomas P, Santiago T, Dallas MH. Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation. Bone Marrow Transplant. 2016;51(5):735-737.
Biliotti E, Palazzo D, Serani M, et al. Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major. Ann Hematol. 2017;96(6):1043-1045.
Sinakos E, Kountouras D, Koskinas J, et al. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol. 2017;178(1):130-136.
Bradley MB, Satwani P, Baldinger L, et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant. 2007;40(7):621-631.